RSS T2 Biosystems Reports Preliminary Financial Results For Q4 And Full Year 2024

Currently reading:
 RSS T2 Biosystems Reports Preliminary Financial Results For Q4 And Full Year 2024

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
10,525
Likes
1,923
Credits
33,567©
Cash
0$
T2 Biosystems, Inc. (TTOO), a biotechnology firm based in Massachusetts, announced its preliminary financial and operational outcomes for the fourth quarter and full year concluding on December 31, 2024.

For the fourth quarter of 2024, the company achieved record product revenues of $2.3 million, contributing to a total of $8.3 million for the year. These results were primarily driven by robust sales of sepsis tests, marking notable increases of 37% and 23% respectively when compared to the previous year.

As of December 31, 2024, T2 Biosystems reported cash and cash equivalents totaling $1.7 million.

John Sperzel, the Chairman and CEO of T2 Biosystems, remarked, "Throughout 2024, we made significant advancements in our business operations. We enhanced our global installed base of T2Dx Instruments and achieved record-breaking sales for our sepsis test panels. This includes unprecedented U.S. sales of the T2Bacteria Panel and outstanding international sales of the T2Resistance Panel. During the fourth quarter, we secured an exclusive U.S. commercial distribution agreement with Cardinal Health, which we anticipate will serve as a catalyst for commercial growth. Cardinal's sales team is undergoing training the week of January 6."

As of Tuesday, T2 Biosystems’ stock is trading at $0.41 on the Nasdaq Capital Market.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips
Top Bottom